The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
10 2021
Historique:
received: 20 10 2020
revised: 18 02 2021
accepted: 16 03 2021
pubmed: 2 5 2021
medline: 26 11 2021
entrez: 1 5 2021
Statut: ppublish

Résumé

The association between intraoperative estimated blood loss and outcomes after pancreatoduodenectomy has, thus far, been rarely explored. In total, 7,706 pancreatoduodenectomies performed at 18 international institutions composing the Pancreas Fistula Study Group were examined (2003-2020). High estimated blood loss (>700 mL) was defined as twice the median. Propensity score matching (1:1 exact-match) was employed to adjust for variables associated with high estimated blood loss and clinically relevant pancreatic fistula occurrence. The study was powered to detect a 33% clinically relevant pancreatic fistula increase in the high estimated blood loss group, with α = 0.05 and β = 0.2. The propensity score model included 966 patients with high estimated blood loss and 966 patients with lower estimated blood loss; all covariate imbalantces were solved. Patients with high estimated blood loss patients experienced higher clinically relevant pancreatic fistula rates (19.4 vs 12.6%, odds ratio 1.66; P < .001), as well as higher severe complication rates (27.8 vs 15.6%), transfusions (50.1 vs 14.3%), reoperations (9.2 vs 4.0%), intensive care unit transfers (9.9 vs 4.8%) and 90-day mortality (4.7 vs 2.0%, all P < .001). High estimated blood loss was an independent predictor for clinically relevant pancreatic fistula (odds ratio 1.78, 95% confidence interval 1.37-2.32), as were prophylactic Octreotide administration (odds ratio 1.95, 95% confidence interval 1.46-2.61) and soft pancreatic texture (odds ratio 5.32, 95% confidence interval 3.74-5.57; all P < .001). Moreover, a second model including 1,126 pancreatoduodenectomies was derived including vascular resections as additional confounder (14.0% vascular resections performed in each group). On multivariable regression, high estimated blood loss was confirmed an independent predictor for clinically relevant pancreatic fistula reduction (odds ratio 1.80, 95% confidence interval 1.32-2.44; P < .001), whereas vascular resection was not (odds ratio 0.64, 95% confidence interval 0.34-1.88; P = .156). This study better establishes the relationship between estimated blood loss and outcomes after pancreatoduodenectomy. Despite inherent contributions to blood loss, its minimization is an actionable opportunity for clinically relevant pancreatic fistula reduction and performance optimization in pancreatoduodenectomy. Accordingly, practical insights are offered to achieve this goal.

Sections du résumé

BACKGROUND
The association between intraoperative estimated blood loss and outcomes after pancreatoduodenectomy has, thus far, been rarely explored.
METHODS
In total, 7,706 pancreatoduodenectomies performed at 18 international institutions composing the Pancreas Fistula Study Group were examined (2003-2020). High estimated blood loss (>700 mL) was defined as twice the median. Propensity score matching (1:1 exact-match) was employed to adjust for variables associated with high estimated blood loss and clinically relevant pancreatic fistula occurrence. The study was powered to detect a 33% clinically relevant pancreatic fistula increase in the high estimated blood loss group, with α = 0.05 and β = 0.2.
RESULTS
The propensity score model included 966 patients with high estimated blood loss and 966 patients with lower estimated blood loss; all covariate imbalantces were solved. Patients with high estimated blood loss patients experienced higher clinically relevant pancreatic fistula rates (19.4 vs 12.6%, odds ratio 1.66; P < .001), as well as higher severe complication rates (27.8 vs 15.6%), transfusions (50.1 vs 14.3%), reoperations (9.2 vs 4.0%), intensive care unit transfers (9.9 vs 4.8%) and 90-day mortality (4.7 vs 2.0%, all P < .001). High estimated blood loss was an independent predictor for clinically relevant pancreatic fistula (odds ratio 1.78, 95% confidence interval 1.37-2.32), as were prophylactic Octreotide administration (odds ratio 1.95, 95% confidence interval 1.46-2.61) and soft pancreatic texture (odds ratio 5.32, 95% confidence interval 3.74-5.57; all P < .001). Moreover, a second model including 1,126 pancreatoduodenectomies was derived including vascular resections as additional confounder (14.0% vascular resections performed in each group). On multivariable regression, high estimated blood loss was confirmed an independent predictor for clinically relevant pancreatic fistula reduction (odds ratio 1.80, 95% confidence interval 1.32-2.44; P < .001), whereas vascular resection was not (odds ratio 0.64, 95% confidence interval 0.34-1.88; P = .156).
CONCLUSION
This study better establishes the relationship between estimated blood loss and outcomes after pancreatoduodenectomy. Despite inherent contributions to blood loss, its minimization is an actionable opportunity for clinically relevant pancreatic fistula reduction and performance optimization in pancreatoduodenectomy. Accordingly, practical insights are offered to achieve this goal.

Identifiants

pubmed: 33931208
pii: S0039-6060(21)00241-5
doi: 10.1016/j.surg.2021.03.044
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1195-1204

Investigateurs

William E Fisher (WE)
George Van Buren (G)
Mark P Callery (MP)
Tara S Kent (TS)
Wande B Pratt (WB)
Charles M Vollmer (CM)
Ammara A Watkins (AA)
Michael G House (MG)
Joal D Beane (JD)
Adam C Berger (AC)
Christopher L Wolfgang (CL)
Ammar A Javed (AA)
Katherine E Poruk (KE)
Kevin C Soares (KC)
Vicente Valero (V)
Carlos Fernandez-Del Castillo (C)
Zhi V Fong (ZV)
Horacio J Asbun (HJ)
John A Stauffer (JA)
Mark P Bloomston (MP)
Mary E Dilhoff (ME)
Ericka N Haverick (EN)
Carl R Schmidt (CR)
John D Christein (JD)
Robert H Hollis (RH)
Chad G Ball (CG)
Elijah Dixon (E)
Steven J Hughes (SJ)
Charles M Vollmer (CM)
Jeffrey A Drebin (JA)
Brett Ecker (B)
Russell Lewis (R)
Matthew McMillan (M)
Benjamin Miller (B)
Priya Puri (P)
Thomas Seykora (T)
Michael J Sprys (MJ)
Amer H Zureikat (AH)
Stacy J Kowalsky (SJ)
Stephen W Behrman (SW)
Claudio Bassi (C)
Fabio Casciani (F)
Laura Maggino (L)
Giuseppe Malleo (G)
Roberto Salvia (R)
Giulia Savegnago (G)
Lorenzo Cinelli (L)
Massimo Falconi (M)
Stefano Partelli (S)
Euan J Dickson (EJ)
Nigel B Jamieson (NB)
Lavanniya K P Velu (LKP)
Ronald R Salem (RR)
John W Kunstman (JW)

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Fabio Casciani (F)

Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Surgery, Unit of General and Pancreatic Surgery, The Pancreas Institute, University of Verona, Italy.

Maxwell T Trudeau (MT)

Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

Horacio J Asbun (HJ)

Department of Surgery, Mayo Clinic, Jacksonville, FL.

Chad G Ball (CG)

Department of Surgery, University of Calgary, Canada.

Claudio Bassi (C)

Department of Surgery, Unit of General and Pancreatic Surgery, The Pancreas Institute, University of Verona, Italy.

Stephen W Behrman (SW)

The University of Tennessee Health Science Center, Memphis, TN.

Adam C Berger (AC)

Department of Surgery, Jefferson Medical College, Philadelphia, PA.

Mark P Bloomston (MP)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.

Mark P Callery (MP)

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

John D Christein (JD)

Department of Surgery, University of Alabama at Birmingham School of Medicine, AL.

Massimo Falconi (M)

Pancreatic Surgery IRCSS San Raffaele Scientific Institute, Milan, Italy.

Carlos Fernandez-Del Castillo (C)

Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Mary E Dillhoff (ME)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.

Euan J Dickson (EJ)

West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.

Elijah Dixon (E)

Department of Surgery, University of Calgary, Canada.

William E Fisher (WE)

Department of Surgery, Baylor College of Medicine, Houston, TX.

Michael G House (MG)

Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.

Steven J Hughes (SJ)

Department of Surgery, University of Florida College of Medicine, Gainesville, FL.

Tara S Kent (TS)

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

John W Kunstman (JW)

Department of Surgery, Yale School of Medicine, New Haven, CT.

Giuseppe Malleo (G)

Department of Surgery, Unit of General and Pancreatic Surgery, The Pancreas Institute, University of Verona, Italy.

Stefano Partelli (S)

Pancreatic Surgery IRCSS San Raffaele Scientific Institute, Milan, Italy.

Christopher L Wolfgang (CL)

Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD.

Amer H Zureikat (AH)

Department of Surgery, University of Pittsburgh Medical Center, PA.

Charles M Vollmer (CM)

Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: Charles.Vollmer@uphs.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH